Marshall Wace
LFCR icon

Marshall Wace’s Lifecore Biomedical LFCR Stock Holding History

Marshall Wace’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$932K Buy
177,471
+119,117
+204% +$600K ﹤0.01% 2232
2026
Q1 		$217K Sell
58,354
-52,267
-47% -$361K ﹤0.01% 2765
2025
Q4 		$905K Sell
110,621
-3,454
-3% -$25.6K ﹤0.01% 1988
2025
Q3 		$840K Buy
114,075
+78,723
+223% +$596K ﹤0.01% 2016
2025
Q2 		$287K Sell
35,352
-32,468
-48% -$219K ﹤0.01% 2340
2025
Q1 		$477K Sell
67,820
-65,371
-49% -$406K ﹤0.01% 2095
2024
Q4 		$990K Sell
133,191
-67,509
-34% -$431K ﹤0.01% 1745
2024
Q3 		$989K Sell
200,700
-99,420
-33% -$519K ﹤0.01% 1653
2024
Q2 		$1.54M Buy
300,120
+139,887
+87% +$828K ﹤0.01% 1486
2024
Q1 		$851K Buy
160,233
+16,340
+11% +$117K ﹤0.01% 1722
2023
Q4 		$891K Buy
143,893
+54,263
+61% +$377K ﹤0.01% 1514
2023
Q3 		$676K Sell
89,630
-37,437
-29% -$342K ﹤0.01% 1625
2023
Q2 		$1.23M Buy
+127,067
New +$776K ﹤0.01% 1631
2022
Q1 		– Sell
-104
Closed -$1K – 3703
2021
Q4 		$1K Buy
+104
New +$1.01K ﹤0.01% 3796

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Marshall Wace's LFCR Position: Q2 2026 in Review

Marshall Wace increased its Lifecore Biomedical (LFCR) stake by 204% in Q2 2026, buying an estimated $600K and bringing the position to 177,471 shares worth $932K. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

Marshall Wace first reported a position in LFCR in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.54M in Q2 2024. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Marshall Wace held 177,471 shares of Lifecore Biomedical worth $932K as of Q2 2026.
  • Marshall Wace bought 119,117 Lifecore Biomedical shares in Q2 2026, an estimated $600K.
  • Lifecore Biomedical made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2232 holding.
  • Marshall Wace first reported a position in Lifecore Biomedical in Q4 2021 and has held it in 14 quarters since.
  • Marshall Wace's Lifecore Biomedical position peaked at $1.54M in Q2 2024.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.